Werewolf Therapeutics (HOWL) vs Milestone Pharmaceuticals (MIST)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Werewolf Therapeutics (HOWL) has outperformed Milestone Pharmaceuticals (MIST) over the past year, gaining 8.4% versus a loss of 84.5%. Over five years, HOWL leads with a -93.7% price change compared with -93.8% for MIST. Milestone Pharmaceuticals is the larger company by market cap ($46.2 million vs $46.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HOWL | MIST |
|---|---|---|
| Share price | $0.9466 | $0.3711 |
| Market cap | $46.00M | $46.20M |
| 1-day change | -3.97% | -7.06% |
| YTD return | +49.31% | -81.63% |
| 1-year return | +8.43% | -84.54% |
| 5-year return | -93.68% | -93.85% |
| EPS (TTM) | $-0.58 | $-0.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-60.82M | $-63.06M |
| 52-week high | $1.20 | $3.06 |
| 52-week low | $0.27 | $0.362 |
| Distance from 52-week high | -21.12% | -87.87% |
| Analyst consensus | none | none |
| Avg. price target upside | +639.49% | +1479.09% |
| Average volume | 1.08M | 1.53M |
| Shares outstanding | 48.60M | 124.50M |
| Employees | 39 | 38 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HOWL has outperformed MIST by 93.0 percentage points over the past year.
About Werewolf Therapeutics
HOWL stock →Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform.
Health Care · Biotechnology: Pharmaceutical Preparations · 39 employees
About Milestone Pharmaceuticals
MIST stock →Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults.
Health Care · Biotechnology: Pharmaceutical Preparations · 38 employees
HOWL vs MIST FAQ
Which is bigger, Werewolf Therapeutics or Milestone Pharmaceuticals?
Milestone Pharmaceuticals (MIST) is larger, with a market capitalization of $46.20M compared with $46.00M for Werewolf Therapeutics (HOWL).
Which stock has performed better over the past year, HOWL or MIST?
HOWL returned +8.43% over the past 12 months, compared with -84.54% for MIST (price return, excluding dividends). Past performance does not predict future results.
Are Werewolf Therapeutics and Milestone Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.